NSE · Healthcare · Drug Manufacturers - General
EPS came in at 6.60 against a street estimate of 5.81 — a beat of 13.6%.
with an average price target of ₹1,571.60.
| Holder | Stake |
|---|---|
| HSBC Mutual Fund - HSBC Multi Cap Fund | 2.87% |
| Manoj Prakash Sanghvi | 1.86% |
| Ratnamani Marketing | 1.82% |
| Bajaj Finserv Flexi Cap Fund | 1.79% |
| Astorne Capital Vcc - Arven | 1.36% |
| Document | Date |
|---|---|
| Annual report FY2026 SENORES PHARMACEUTICALS LIMITED - ANNUAL REPORT 2025-26 SUMMARY HEADLINE NUMBERS • Market Capitalization (as of March 31, 2026): ₹3,490.40 Crores • | 2026-09-03 |
| Q1 FY27 earnings call SENORES PHARMACEUTICALS LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Consolidated revenue from operations: INR 180 crores (Q1 FY27), up 36% Y-o-Y • | 2026-08-03 |
| Investor presentation SENORES PHARMACEUTICALS LIMITED – Q1 FY27 INVESTOR SUMMARY --- HEADLINE NUMBERS • Revenue Q1FY27: ₹180.2 Crs, up 36% Y-o-Y (Q1FY26: ₹132.6 Crs) • | 2026-07-27 |
| Q4 FY26 earnings call SENORES PHARMACEUTICALS LIMITED – Q4 FY26 SUMMARY --- HEADLINE NUMBERS • FY26 Total Revenue: INR 664 crores (62% Y-o-Y growth vs FY25) • FY26 Profi | 2026-05-19 |
| Investor presentation · Q4 FY26 SENORES PHARMACEUTICALS LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Total Income FY26: Rs. 664.0 crores, up 61.8% year-on-year (Q4FY26: Rs. 189.7 | 2026-05-14 |
| Quarterly results · Q4 FY26 SENORES PHARMACEUTICALS LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Q4 FY26 Total Income: Rs. 190 Cr (+66% Y-o-Y) • Q4 FY26 EBITDA: Rs. 62 Cr (+2 | 2026-05-14 |
| Q3 FY26 earnings call SENORES PHARMACEUTICALS LIMITED – Q3FY26 SUMMARY HEADLINE NUMBERS • Q3FY26 consolidated revenue: INR175 crores (64% YoY growth) • 9MFY26 consolidate | 2026-01-27 |
| Investor presentation · Q3 FY26 SENORES PHARMACEUTICALS LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Total Income Q3FY26: Rs. 174.6 crores (up 64% Y-o-Y from Rs. 106.4 crores) • T | 2026-01-20 |
Readable in the app.
| Announcement | Date |
|---|---|
| Capacity expansion announced Senores Pharmaceuticals said its subsidiaries plan to expand manufacturing capacity, with completion targeted by March 2027. Havix Group Inc. in the US will increase annual capacity from 1.2 | 2026-10-29 |
| Company informed about acquisition updates Senores Pharmaceuticals Limited has informed the Exchange regarding updates on acquisition | 2026-01-16 |
| Acquisition of another business or entity completed Senores Pharmaceuticals Limited has informed the Exchange regarding Acquisition | 2025-12-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for SENORES PHARMACEUTICALS L — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.